Drug intelligence / Profile preview

BIBW22 BS

Development stage: Unknown
Modality: Small Molecules
Administration: Oral

Overview

BIBW22 BS is a phenylpteridine analog that functions as a potent multidrug resistance (MDR)-reversing agent. It directly interacts with P-glycoprotein (P-gp), a protein found in tumor cells that contributes to the MDR phenotype by facilitating drug transport across cell membranes. Unlike some other P-gp inhibitors, BIBW22 BS is not effluxed from drug-resistant cells and instead accumulates within them, thereby inhibiting the photolabeling of P-gp.

Other names: {[3H]azido-4-[N-(2-hydroxy-2-methylpropyl)-ethanolamino]-2, 7-bis(cis-2,6-dimethyl-morpholino)-6-phenylpteridine}

Targets

ABCB1 (P-glycoprotein)

Beyond the preview

Go deeper on BIBW22 BS.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BIBW22 BS.

Explore the full profile